Who is best placed to carry each risk?
LinkedIn caption
🤝 Who is best placed to carry each risk?
Cailin McGurk of Morgan Stanley moderated ARDD 2026’s discussion of late-stage therapeutic assets and licensing. The official recap contrasts acquisitions, where the buyer absorbs risk, with licensing structures that share it through milestones and royalties.
💡 For aging-focused companies, the conversation connects financing strategy with scientific readiness. Stronger translational evidence and a clearer regulatory path can support larger commitments as the field matures. The choice of deal structure helps determine how partners move a promising program forward together.
#ARDD2026 #DrugDiscovery
X caption
🤝 Who should carry each risk in a longevity deal? Cailin McGurk’s #ARDD2026 panel connected licensing structures with translational evidence and regulatory clarity. Milestones and royalties can distribute risk across development.
#DrugDiscovery
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
